Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma



Ahmadzadehfar H1, 2 ; Aryana K3 ; Pirayesh E2 ; Farzanehfar S4 ; Assadi M5 ; Fallahi B6 ; Shafiei B2 ; Ayati N3 ; Amoui M2
Authors

Source: Iranian Journal of Nuclear Medicine Published:2018

Abstract

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with continuously increasing interest and use worldwide. This guideline is intended to assist nuclear medicine physicians in evaluating and managing patients with mRCPC for whom radioligand therapy (RLT) using 177Lu-PSMA is a promising treatment option. In addition, more information could be provided by subsequent investigative studies in the field of RLT. © 2018 Tehran University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Historical Review of Pharmacological Development and Dosimetry of Psma-Based Theranostics for Prostate Cancer, Journal of Radioanalytical and Nuclear Chemistry (2019)
2. Factors Predicting the Early Biochemical Response to [177Lu]Lu-Psma Therapy in Patients With Metastatic Castration Resistant Prostate Cancer, Iranian Journal of Nuclear Medicine (2022)
3. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (6)
Parham Geramifar (6)
Other Related Docs
4. Predictive and Prognostic Potential of Pretreatment 68Ga-Psma Pet Tumor Heterogeneity Index in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With 177Lu-Psma, Frontiers in Oncology (2022)
5. Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen, Bioorganic Chemistry (2020)
6. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends, Cancers (2021)
7. Therapeutic Outcomes Of177lu-Psma Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study, Asia Oceania Journal of Nuclear Medicine and Biology (2023)
8. Passive-Specific Immunotherapy With Monoclonal Antibodies for Prostate Cancer: A Systematic Review, Journal of Oncology Pharmacy Practice (2019)
9. Prognostic Significance of Baseline Clinical and [68Ga]Ga-Psma Pet Derived Parameters on Biochemical Response, Overall Survival, and Psa Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Undergoing [177Lu]Lu-Psma Therapy, Nuklearmedizin - NuclearMedicine (2024)
10. Personalized Dosimetry Assessment of [177Lu]Lu-Psma-617 Radioligand Therapy in the Management of Metastatic Castration-Resistant Prostate Cancer, International Journal of Radiation Biology (2024)
11. 99Mtc-Psma Spect/Ct Versus 68Ga-Psma Pet/Ct in the Evaluation of Metastatic Prostate Cancer, Clinical Nuclear Medicine (2021)
12. 68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression, Clinical Nuclear Medicine (2022)
13. Preparation and Biodistribution Assessment of 68Ga-Dkfz-Psma-617 for Pet Prostate Cancer Imaging, Nuclear Science and Techniques (2016)
14. Selection of Single Chain Antibody Fragments for Targeting Prostate Specific Membrane Antigen: A Comparison Between Cell-Based and Antigen-Based Approach, Protein and Peptide Letters (2016)
15. Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-Psma Pet/Ct in Prostate Cancer: A Comparative Study, Journal of Clinical Medicine (2020)
16. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens, Diagnostics (2024)
17. An Update on the Role of Mpmri and 68Ga-Psma Pet Imaging in Primary and Recurrent Prostate Cancer, Clinical Genitourinary Cancer (2024)
18. Prostate Cancer and Tumor Microenvironment, Prostate Cancer: Molecular Events and Therapeutic Modalities (2024)
19. Optimized Production, Quality Control, Biological Evaluation and Pet/Ct Imaging of 68Ga-Psma-617 in Breast Adenocarcinoma Model, Radiochimica Acta (2017)
20. Glutamate-Urea-Based Psma-Targeted Plga Nanoparticles for Prostate Cancer Delivery of Docetaxel, Pharmaceutical Development and Technology (2021)